Search results for "checkpoint inhibition"

showing 3 items of 3 documents

Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets

2021

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentRetinoic acidchemistry.chemical_compoundNeuroblastoma0302 clinical medicineTumor Microenvironment11q deletion anti-GD2 immunotherapy combination immunotherapy immune cell infiltration miRNAs neuroblastomaMedicineeducation.field_of_studyimmune cell infiltration11q deletionImmunosuppressionGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPatologiaNeoplasm ProteinsmicroRNAsSurvival Rateanti‐GD2 therapyOncology030220 oncology & carcinogenesiscombination immunotherapymiRNAsMolecular Medicineimmune checkpoint inhibitionFemaleImmunotherapyChromosome Deletionanti‐GD2 immunotherapyPopulationlcsh:RC254-282Disease-Free Survival03 medical and health sciencesImmune systemNeuroblastomaGeneticsImmune ToleranceHumanseducationRetrospective Studiesbusiness.industryChromosomes Human Pair 11Immunotherapymedicine.diseaseImmune checkpointBlockade030104 developmental biologychemistryCancer researchCommentarybusiness
researchProduct

Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC

2020

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negat…

MaleAPOBECCancer ResearchT-Lymphocytesmedicine.medical_treatment610BiologyCohort Studies03 medical and health sciences0302 clinical medicineGene expressionBiomarkers TumormedicineHumansExomeAPOBEC Deaminasestumor inflammationPapillomaviridaeExomeGeneImmune EvasionInflammationSequence Analysis RNASquamous Cell Carcinoma of Head and NeckPapillomavirus InfectionsAPOBECmutational signatureImmunotherapyMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaPhenotypeImmune checkpointddc:Gene Expression Regulation Neoplasticstomatognathic diseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisMutationCancer researchimmune checkpoint inhibitionFemalehead and neck cancerTranscriptome600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitInternational Journal of Cancer
researchProduct

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma

2018

Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM cells at specific time points: at diagnosis and before and after autologous stem cell transplantation. Remarkably, after cytokine stimulation, the patients' NK cells did not significantly differ from those of healthy donors. In a small cohort of MM patients…

multiple myelomalcsh:Immunologic diseases. Allergyautologous stem cell transplantationcheckpoint inhibitionadoptive cell therapyNK cellsNKG2A blockinglcsh:RC581-607Frontiers in Immunology
researchProduct